CORAL GABLES, FL / ACCESSWIRE / October 14, 2015 / Despite the woes that oil has faced there seems to be no end to the current glut. In recent news the oversupply and lack of demand continues to increase and one of the larger producers, Russia, who is not part of OPEC says they will not cut output. Russia’s Energy Minister Alexander Novak told CNBC, “The gas and oil industry is one of the most important industries in Russia…(But) with respect to Russia’s export influence on global markets in the past years, we have maintained our output rate pretty much unchanged over the past three to four years, but we have witnessed a lot of inflow, of a lot shale oil from the United States.”
Despite these shortcomings, other opportunities may have presented themselves. On the heels of the Democratic Debate, candidate Hillary Clinton has been more popularly known for giving biotech a beating in past week however the market for some biotechnology stocks have begun to actually increase. Which stocks have seen this rebound? Companies like SciVac Therapeutics Inc. (SVACF), Progressive care Inc (RXMD), and RXi Pharmaceuticals Corporation (RXII) have seen a mix of market activity and company news during earnings season increase trading activity as well as price during the third week of October.
SciVac Therapeutics Inc. (SVACF) is developing, manufacturing and promoting biological products for human healthcare. The Company’s flagship product, SciVac(TM), is a recombinant 3rd generation hepatitis B vaccine. SVACF releases details that its wholly-owned subsidiary SciVac Ltd. has obtained a green light from the Israeli Ministry of Health to continue all standard manufacturing, including labeling and release of Sci-B-Vac(TM) to the market, following corrective actions to the automated labeling system and an inspection of the Company’s facilities earlier in the month of September. SVACF is up from last Friday’s close increasing 13% following highs of $0.0195 on Tuesday. In previous news it was cited that Opko Health, Inc. (OPKO) had a 45% stake in SciVac. Sci-B-Vac has demonstrated performance in 20+ company-sponsored or investigator- initiated trials, involving more than 5000 enrollees while also being administered to over 500,000 patients to date, with favorable safety and efficacy profiles according to company data.
Progressive care Inc. (RXMD), through its subsidiary PharmCo, LLC, is a South Florida provider of prescription pharmaceuticals working in health practice risk management, the sale of anti-retroviral medications and related medication therapy treatment. The pharmacy filled over 17,000 prescriptions during the month, which equated to nearly a 30% increase over the same month this past year. In addition, this was close to 4% higher than the past month. Moving along, the third quarter of this year, PharmCo filled over 50,000 prescriptions documenting the best sales quarter for the company to date. Tuesday RXMD saw gains of 73% from Monday’s close following highs of nearly $0.01. Through the first nine months of this year the company reached nearly $10 million in revenues, achieved positive cash flow and operating profitability.
RXi Pharmaceuticals Corporation (RXII) is another biotech company and is dedicated to discovering and creating innovative therapeutics primarily in the areas of dermatology and ophthalmology that identify high-unmet medical needs. The Company’s development systems are based on siRNA technology as well as immunotherapy agents. These compounds involve, but are not limited to, their proprietary, self-delivering RNAi (sd-rxRNA(R)) compounds for the treatment of dermal and ocular scarring. RXII has seen significant gains amounting to an increase of 74.5% since the end of September to Tuesday’s highs. In recent press, RXi announced that Dr. Robert Galiano, one of the Company’s Principal Investigators for the RXI-109 clinical program, will present during The Plastic Surgery Foundation (PSF) Industry Summit on Sunday, October 18, 2015.
About Biotech Stocks (www.BiotechStocks.com)
Biotech Stocks (www.biotechstocks.com) is your best resource for today’s emerging biotech industry. Whether you’re looking for the best biotech stocks to buy, biotech news, trends in biotech, articles within the biotech industry and so much more, BiotechStocks.com is your destination for it all. Our goal is to become the central hub for all who are seeking current Biotech Stock News as well as biotech industry, political and social news, articles, trends & overall insight, delivered in a way that we all can relate to.
Except for the historical information presented herein, matters discussed in this article contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. BiotechStocks.com, is not registered with any financial or securities regulatory authority, and does not provide nor claims to provide investment advice or recommendations to readers of this release. BiotechStocks.com, may from time to time have a position in the securities mentioned herein and may increase or decrease such positions without notice. For making specific investment decisions, readers should seek their own advice. BiotechStocks.com, may be compensated for its services in the form of cash-based compensation or equity securities in the companies it writes about, or a combination of the two. MAPH Enterprises LLC BiotechStocks.com | was paid an advertising fee of $30,000 cash & ZERO shares by a non affiliate 3rd party share holder for visual sponsorship on BiotechStocks.com and for visual placement of SVCAF within written materials for a duration of 30 days beginning 10/12/2015 and ending 11/12/2015.